Source: http://archive-ie.com/ie/n/ncpe.ie/2015-10-30_6909014_26/NCPE_Pembrolizumab_Keytruda_Assessment_National_Centre_for_Pharmacoeconomics/
Timestamp: 2017-08-17 13:38:10
Document Index: 439248204

Matched Legal Cases: ['art 2', 'art 3', 'art 4', 'art 5', 'art 6', 'art 7']

archive-ie.com: ncpe.ie - NCPE Pembrolizumab (Keytruda®) Assessment | National Centre for Pharmacoeconomics
NCPE Pembrolizumab (Keytruda®) Assessment | National Centre for Pharmacoeconomics
Submission Templates Pharmacoeconomic Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Pembrolizumab Keytruda In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Keytruda is indicated as monotherapy in the treatment of unresectable or metastatic melanoma in adults Rapid Review Commenced Completed Outcome 06 08 2015 13 08 2015 Full Pharmacoeconomic Evaluation Recommended
Original URL path: http://www.ncpe.ie/drugs/pembrolizumab-keytruda/ (2015-10-30)
Tedizolid phosphate (Sivextro®) | National Centre for Pharmacoeconomics
Evaluations Drugs Vaccines Diagnostics and Other Technologies Publications Peer Reviewed Papers Abstracts Reports Research Drug Utilisation Research Pharmacoeconomic Research ICORN Education Tedizolid phosphate Sivextro In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Tedizolid phosphate Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections ABSSSI in adults Rapid Review Commenced Completed Outcome 07 05 2015 07 07 2015 Full pharmacoeconomic
Original URL path: http://www.ncpe.ie/drugs/tedizolid-phosphate-sivextro/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 2
Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Ceritinib Zykadia July 22 2015 Nivolumab Opdivio for NSCLC July 16 2015 Nivolumab Opdivio for Melanoma July 16 2015 Camellia sinensis folium green tea leaf Catephen 10 July 14 2015 Lenvatinib Lenvima July 10 2015 Edoxaban Lixiana July 10 2015 Omalizumab Xolair for the treatment of severe allergic asthma June 25 2015 Enzalutamide Xtandi pre chemotherapy June 22 2015
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/2/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 3
Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Ruxolitinib Jakavi for Polycythaemia Vera May 28 2015 Romiplostim Nplate May 27 2015 Elosulfase alfa Vimizim May 8 2015 Insulin Degludec Tresiba May 6 2015 Naloxegel Moventig April 13 2015 Apremilast Otezla for psoriatic arthritis April 3 2015 Apremilast Otezla for moderate to severe chronic plaque psoriasis April 3 2015 Obinutuzumab Gazyvaro April 2 2015 Pixantrone Pixuvri March
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/3/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 4
In this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Pomalidomide Imnovid March 13 2015 Nintedanib Ofev February 26 2015 Bedaquiline Sirturo February 20 2015 Olaparib Lynparza February 19 2015 Nintedanib Vargatef February 10 2015 Aclidinium bromide formoterol fumarate dihydrate Brimica Genuair February 9 2015 Dimethyl fumarate Tecfidera January 16 2015 Dasabuvir 250mg Exviera January 15 2015 Ombitasvir 12 5mg and paritaprevir 75mg and ritonavir 50mg
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/4/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 5
this Section Pharmacoeconomic Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Darunavir cobicistat Rezolsta January 8 2015 Idelalisib Zydelig December 31 2014 Ramucirumab Cyramza December 30 2014 Ataluren Translarna December 23 2014 Pegylated Interferon beta 1a Plegridy December 22 2014 Ledipasvir sofosbuvir Harvoni December 18 2014 Ofatumumab Arzerra Previously untreated Chronic Lymphocytic Leukaemia December 18 2014 Pregabalin Lyrica for the treatment of Generalised Anxiety Disorder December 15 2014
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/5/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 6
Evaluations Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Sofosbuvir Solvaldi November 13 2014 Polynuclear iron III oxyhydroxide pn FeOOH Velphoro October 8 2014 Regorafenib Stivarga for GIST October 6 2014 Delta 9 tetrahydrocannabinol THC Cannabidiol CBD Sativex October 3 2014 Vedolizumab Entyvio in Crohn s Disease October 1 2014 Vedolizumab Entyvio in Ulcerative Colitis October 1 2014 Rituximab MabThera September 24 2014 Lomitapide Lojuxta September 15 2014 Mannitol
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/6/ (2015-10-30)
Latest Drugs | National Centre for Pharmacoeconomics - Part 7
Drugs Latest Drugs Vaccines Diagnostics and Other Technologies Archive Canagliflozin Invokana September 1 2014 Insulin aspart NovoRapid FlexTouch August 28 2014 Apixaban Eliquis for treatment of deep vein thrombosis DVT and pulmonary embolism PE and prevention of recurrent DVT and PE in adults August 13 2014 Cabozantinib COMETRIQ August 13 2014 Aripiprazole Abilify Maintena August 7 2014 Lixisenatide Lyxumia August 7 2014 Tocilizumab SC RoActemra July 16 2014 Defibrotide Defitelio
Original URL path: http://www.ncpe.ie/pharmacoeconomic-evaluations/all-drug/drugs/page/7/ (2015-10-30)